WO2021255681A1 - A simple process for the preparation of favipiravir and its intermediates thereof - Google Patents

A simple process for the preparation of favipiravir and its intermediates thereof Download PDF

Info

Publication number
WO2021255681A1
WO2021255681A1 PCT/IB2021/055354 IB2021055354W WO2021255681A1 WO 2021255681 A1 WO2021255681 A1 WO 2021255681A1 IB 2021055354 W IB2021055354 W IB 2021055354W WO 2021255681 A1 WO2021255681 A1 WO 2021255681A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
preparation
favipiravir
amide
fluoro
Prior art date
Application number
PCT/IB2021/055354
Other languages
French (fr)
Inventor
Sudhir Nambiar
Goverdhan Gilla
Nageshwar Gunda
Narayan Subhash Chakor
Ramesh Mokal
Rahul Bhalerao
Kiran Avinash Bapat
Hemant Prabhakar PIMPARKAR
Rajamouli Srihari SAMALA
Original Assignee
Hikal Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hikal Limited filed Critical Hikal Limited
Publication of WO2021255681A1 publication Critical patent/WO2021255681A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to a simple process for the preparation of Favipiravir of formula (I).
  • the present invention further relates to an improved process for the preparation of substantially pure 2-aminomalonamide of formula (II) a key starting material of Favipiravir.
  • Favipiravir 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide known as Favipiravir is a compound which is originally useful for the prevention and treatment of viral infectious diseases, particularly influenza viral infectious diseases.
  • Favipiravir has become popular because it is said to be a promising compound for the treatment of infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • Many pharmaceutical companies have urgently started clinical trials to prove the efficacy for treating the said disease using Favipiravir.
  • manufacturing the Favipiravir and substantially pure key starting material 2- aminopropanediamide in a simple and economical process has become urgent priority.
  • JP2010241805A and the like have disclosed process for preparation of Favipiravir and 2-aminopropanediamide.
  • the known processes however, have one or the other disadvantages, for example, those as mentioned below: (i) involve more number of reaction steps; (ii) involvement of explosive step i.e, concentrating hydroxyiminomalonate; (iii) the intermediate for manufacturing Favipiravir is either a labile compound or having less purity; (iv) troublesome operations such as extraction, column chromatography and removal of the solvent by distillation are necessary; (v) harmful reaction/reagents involvement and (vi) the yield is low.
  • the inventors of the present invention have developed a simple process to produce Favipiravir in two reaction steps and a substantially pure intermediate of 2-aminomalonamide.
  • One aspect of the present invention is to provide a two-step process for the preparation of Favipiravir of formula (I) from 2-aminomalonamide.
  • the present invention relates to a process for the preparation of Favipiravir of formula (I) using suitable fluorinating agent.
  • the present invention relates to a process for the preparation of Favipiravir of formula (I) where the process comprises the steps of:
  • the present invention relates to a process for the preparation Favipiravir of formula (I) where pyrazine-amide of formula (III) where R is hydrogen, metal ion; is reacted with suitable fluorinating agent to Favipiravir of formula (I).
  • 2-aminomalonamide of formula (II) is substantially pure having purity greater than 95%, where dimer impurity less than 5%, and a cyclic amide impurity less than 0.5%.
  • the present invention relates to a process for the preparation of a substantially pure 2-aminopropanediamide of formula (II) having a dimer impurity less than 5% and a cyclic amide impurity less than 0.5%.
  • Favipiravir of formula (I) is prepared from readily available 2-aminomalonamide of formula (II) or prepared by a process disclosed in present invention.
  • the present invention relates to a substantially pure 2- aminomalonamide (II), which is prepared by a process comprising steps of:
  • Favipiravir of formula (I) is prepared from pyrazine-amide of formula (III) where R is hydrogen, metal ion.
  • solvent used herein refers to the single solvent or mixture of solvents.
  • the suitable reagent in preparation of compound formula (III) is a base which is selected from inorganic base or organic base.
  • inorganic base is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, potassium bicarbonate
  • organic base is selected from triethyl amine, diisopropylethylamine amine and tert-butyl amine.
  • metal ion salt is sodium or potassium.
  • phase transfer catalyst is selected from 18 crown ethers, tetrabutylphosphonium bromide, tetrabutyl ammonium bromide (TBAB), tetrabutyl ammonium fluoride (TBAF), tetrabutyl ammonium chloride, tetrabutyl ammonium iodide or any other PTC known in the art.
  • fluorination is carried out using any suitable fluorinating agent which is known to a person skilled in the art.
  • suitable fluorinating agent is selected from selectfluor (l-Chloromethyl-4-fluoro-l,4-diazoniabicyclo [2.2.2] octane bis (tetrafluoroborate)), 1 -Fluoropyridinium tetrafluoroborate, 1- chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis
  • fluorinating reaction is carried-out in presence solvent, which is selected from acetone, methyl isobutyl ketone, acetonitrile, methyl tert-butyl ether, isopropyl ether, cyclohexane, heptane, toluene, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, and dimethyl sulfoxide.
  • solvent which is selected from acetone, methyl isobutyl ketone, acetonitrile, methyl tert-butyl ether, isopropyl ether, cyclohexane, heptane, toluene, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, and dimethyl sulfoxide.
  • fluorinating reaction is carried out at ambient to reflux temperature, and for 10-12 hours.
  • dialkyl malonate (1) wherein Ri is C1-C4 alkyl is preferably dimethyl malonate and diethyl malonate.
  • the acid used for preparation of compound (2) is selected from hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or methanesulfonic acid.
  • the solvent used for isolation of compound (2) is selected from ether solvent such as diethyl ether, diisopropyl ether, methyl-t-butyl ether, methoxybenzene; ester solvent such as ethyl acetate, n-butyl acetate; aliphatic hydrocarbons such as hexane, heptane, cyclohexane; and halogen solvent such as chloroform and methylene chloride.
  • ether solvent such as diethyl ether, diisopropyl ether, methyl-t-butyl ether, methoxybenzene
  • ester solvent such as ethyl acetate, n-butyl acetate
  • aliphatic hydrocarbons such as hexane, heptane, cyclohexane
  • halogen solvent such as chloroform and methylene chloride.
  • catalyst which is selected from nickel, palladium, ruthenium, rhodium, with or without support; platinum oxide, sodium borohydride, Lithium aluminium hydride; preferably from palladium on carbon, platinum on carbon, Raney nickel.
  • the solvent used in reduction reaction is selected from methanol, ethanol, and isopropanol.
  • dialkyl malonate (1, 1.0 kg) was charged and cooled at 0°C to 5°C.
  • acetic acid solution (1197 g acetic acid in 1620 ml water) was slowly added maintaining the temperature below 10°C and further cooled to 0°C to 5°C.
  • sodium nitrite (1300g) was charged portion wise under stirring at same temperature.
  • the reaction mixture was allowed to room temperature (RT) and stirred for 15 to 40 min. Further, the temperature was raised to 40°C to 50°C and stirred for 2 to 3 hours. The reaction completion was ensured by GC and cooled to 25°C to 30°C.
  • the reaction mixture was cooled to 25°C to 30°C and filtered through hyflo bed.
  • An autoclave was flushed with methanol (100 mL) and the flushing was used for washing the hyflo bed.
  • the filtrate and washings were combined, and it was transferred into the cleaned autoclave (10 L).
  • the autoclave was flushed with Nitrogen (minimum 2 Kg/cm 2 ).
  • the reaction mixture was cooled at -10°C to 10°C.
  • the ammonia gas pressure (2 to 3 Kg/cm 2 ) was applied at temperature below 10°C.
  • the reaction mixture was allowed to 15°C to 20°C and stirred for 4 to 12 hours maintaining the pressure at 2 to 3 Kg/cm 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a simple process for the preparation of Favipiravir of Formula (I). The present invention further relates to an improved process for the preparation of substantially pure 2-aminomalonamide of formula (II) a key starting material of Favipiravir.

Description

“A SIMPLE PROCESS FOR THE PREPARATION OF FAVIPIRAVIR AND ITS INTERMEDIATES THEREOF”
RELATED APPLICATION
This application claims combined benefit of Indian provisional application no. 202021025469, filed on June 17, 2020, and 202021030969, filed on July 20, 2020; the contents of which were incorporated by reference herein.
FIELD OF INVENTION
The present invention relates to a simple process for the preparation of Favipiravir of formula (I). The present invention further relates to an improved process for the preparation of substantially pure 2-aminomalonamide of formula (II) a key starting material of Favipiravir.
Figure imgf000002_0001
(I) (II)
BACKGROUND OF THE INVENTION
6-Fluoro-3-hydroxy-2-pyrazinecarboxamide known as Favipiravir is a compound which is originally useful for the prevention and treatment of viral infectious diseases, particularly influenza viral infectious diseases. Suddenly Favipiravir has become popular because it is said to be a promising compound for the treatment of infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many pharmaceutical companies have urgently started clinical trials to prove the efficacy for treating the said disease using Favipiravir. Hence manufacturing the Favipiravir and substantially pure key starting material 2- aminopropanediamide in a simple and economical process has become urgent priority.
Numerous patents/patent applications such as USRE43748 El, US8168789 B2, EP1256588 Bl, WO 2018/003946 Al, CN 107226794 A, J. Am. Chem. Soc., 1948, vol. 71, page 78-80, WO2007144686A1, US8664405B2, and
JP2010241805A and the like, have disclosed process for preparation of Favipiravir and 2-aminopropanediamide. The known processes, however, have one or the other disadvantages, for example, those as mentioned below: (i) involve more number of reaction steps; (ii) involvement of explosive step i.e, concentrating hydroxyiminomalonate; (iii) the intermediate for manufacturing Favipiravir is either a labile compound or having less purity; (iv) troublesome operations such as extraction, column chromatography and removal of the solvent by distillation are necessary; (v) harmful reaction/reagents involvement and (vi) the yield is low.
To overcome the limitations of the processes known in the art, the inventors of the present invention have developed a simple process to produce Favipiravir in two reaction steps and a substantially pure intermediate of 2-aminomalonamide.
SUMMARY OF THE INVENTION
One aspect of the present invention is to provide a two-step process for the preparation of Favipiravir of formula (I) from 2-aminomalonamide.
In another aspect, the present invention relates to a process for the preparation of Favipiravir of formula (I) using suitable fluorinating agent.
In another aspect, the present invention relates to a process for the preparation of Favipiravir of formula (I) where the process comprises the steps of:
(a) reacting 2-aminomalonamide of formula (II) with glyoxal in presence of suitable reagent to afford pyrazine-amide of formula (III) where R is hydrogen, metal ion;
Figure imgf000003_0001
(II) (III) (b) fluorinating the pyrazine-amide of formula (III) using suitable fluorinating agent to obtain Favipiravir of formula (I)
Figure imgf000004_0001
In another aspect, the present invention relates to a process for the preparation Favipiravir of formula (I) where pyrazine-amide of formula (III) where R is hydrogen, metal ion; is reacted with suitable fluorinating agent to Favipiravir of formula (I).
Figure imgf000004_0002
In one embodiment of the invention where the 2-aminomalonamide of formula (II) is reacted with glyoxal in presence of suitable reagent to afford pyrazine- amide of formula (III) where R is hydrogen, metal ion.
In one embodiment of the invention where 2-aminomalonamide of formula (II) is substantially pure having purity greater than 95%, where dimer impurity less than 5%, and a cyclic amide impurity less than 0.5%.
In another aspect, the present invention relates to a process for the preparation of a substantially pure 2-aminopropanediamide of formula (II) having a dimer impurity less than 5% and a cyclic amide impurity less than 0.5%.
Figure imgf000004_0003
(dimer impurity) (cyclic amide impurity) In another aspect, the present invention where Favipiravir of formula (I) is prepared from readily available 2-aminomalonamide of formula (II) or prepared by a process disclosed in present invention.
In another aspect, the present invention relates to a substantially pure 2- aminomalonamide (II), which is prepared by a process comprising steps of:
(a) reacting a dialkyl malonate (1) wherein Ri is Ci-C4alkyl, with sodium or potassium nitrite in water in presence of acid to obtain dialkylhydroxyiminomalonate(2);
Figure imgf000005_0001
(b) reducing dialkyl hydroxyiminomalonate(2) using hydrogenating agent in a solvent to obtain dialkyl aminomalonate (3), which is further treated with ammonia in solvent to obtain 2-aminomalonamide of formula (II)
Figure imgf000005_0002
In another aspect, the invention where Favipiravir of formula (I) is prepared from pyrazine-amide of formula (III) where R is hydrogen, metal ion.
In another aspect, the invention where pyrazine-amide of formula (III) is isolated as free acid or corresponding metal ion salt.
DETAILED DESCRIPTION OF THE INVENTION
The present invention now will be described more detail hereinafter. The invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. As used in the specification, and in the appended claims, the singular forms “a”, “an”, “the”, include plural referents unless the context clearly indicates otherwise.
The preparation of the starting materials and reagents used in the present invention are well known in prior art.
The term solvent used herein, refers to the single solvent or mixture of solvents.
In another embodiment the process for the preparation of Favipiravir of formula (I) is illustrated in following synthetic scheme:
Figure imgf000006_0001
(II) (III) (I) where R is hydrogen or metal
In one embodiment of the invention where glyoxal which is used in less than 50% concentration.
In another embodiment of present invention, wherein the suitable reagent in preparation of compound formula (III) is a base which is selected from inorganic base or organic base.
In another embodiment of present invention, wherein inorganic base is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, potassium bicarbonate, and organic base is selected from triethyl amine, diisopropylethylamine amine and tert-butyl amine.
In another embodiment of the invention, wherein metal ion salt is sodium or potassium.
In another embodiment of present invention, wherein preparation of compound (III) is carried out at ambient to reflux temperature, and for 4-6 hours (hrs.). In another embodiment of the invention, wherein fluorinating reaction is carried- out in presence or absence of phase transfer catalyst (PTC).
In another embodiment of the invention, wherein phase transfer catalyst (PTC) is selected from 18 crown ethers, tetrabutylphosphonium bromide, tetrabutyl ammonium bromide (TBAB), tetrabutyl ammonium fluoride (TBAF), tetrabutyl ammonium chloride, tetrabutyl ammonium iodide or any other PTC known in the art.
In another embodiment of the invention, wherein fluorination is carried out using any suitable fluorinating agent which is known to a person skilled in the art.
In another embodiment of the invention, wherein suitable fluorinating agent is selected from selectfluor (l-Chloromethyl-4-fluoro-l,4-diazoniabicyclo [2.2.2] octane bis (tetrafluoroborate)), 1 -Fluoropyridinium tetrafluoroborate, 1- chloromethyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis
(hexafluorophosphate) (FTEDA-PF6), l-methyl-4-fluoro-l,4- diazoniabicyclo[2.2.2]octane bis(tetrafluoro borate) (Selectfluor II), l-methyl-4- fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(hexafluorophosphate) (Selectfluor II- PF6), N-fluorobenzenesulfonimide (NFSI) and Me-NFSI, l-fluoro-4-hydroxy- l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (NFTh) and (l-fluoro-1,3- dihydro-3 ,3-dimethyl- 1 ,2-benziodoxle) fluorobenziodoxole.
In another embodiment of present invention, wherein fluorinating reaction is carried-out in presence solvent, which is selected from acetone, methyl isobutyl ketone, acetonitrile, methyl tert-butyl ether, isopropyl ether, cyclohexane, heptane, toluene, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, and dimethyl sulfoxide.
In another embodiment of present invention, wherein fluorinating reaction is carried out at ambient to reflux temperature, and for 10-12 hours.
In another embodiment the process for the preparation of substantially pure 2- aminomalonamide of formula (II) is illustrated in the following synthetic scheme:
Figure imgf000008_0001
In another embodiment of the present invention, wherein the dialkyl malonate (1) wherein Ri is C1-C4 alkyl is preferably dimethyl malonate and diethyl malonate.
In another embodiment of the invention, wherein the acid used for preparation of compound (2) is selected from hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or methanesulfonic acid.
In another embodiment of the invention, wherein the solvent used for isolation of compound (2) is selected from ether solvent such as diethyl ether, diisopropyl ether, methyl-t-butyl ether, methoxybenzene; ester solvent such as ethyl acetate, n-butyl acetate; aliphatic hydrocarbons such as hexane, heptane, cyclohexane; and halogen solvent such as chloroform and methylene chloride.
In another embodiment of the invention, wherein reduction reaction is performed by using hydrogen in presence of catalyst, which is selected from nickel, palladium, ruthenium, rhodium, with or without support; platinum oxide, sodium borohydride, Lithium aluminium hydride; preferably from palladium on carbon, platinum on carbon, Raney nickel.
In another embodiment of the invention, wherein the solvent used in reduction reaction is selected from methanol, ethanol, and isopropanol.
In an embodiment, of the present invention, wherein the process for the preparation of substantially pure 2-aminomalonamide of formula (II) having purity greater than 95% and with minimize the formation of dimer impurity less than 5%, preferably less than 3% and a cyclic amide impurity less than 0.5%.
Figure imgf000009_0001
(dimer impurity) (cyclic amide impurity)
The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.
EXPERIMENTAL
Example 1: Preparation of Favipiravir formula (I)
Step-1: Preparation of compound formula (III)
In a Round bottom flask (RBF), sodium hydroxide (25.63 g, 0.6407 mol), water (lOO.OmL) was added and cooled -10 to -5°C. To this solution 2- aminomalonamide (II, 50 gm, 0.4271 mol) added and stirred and a 40% aq. Glyoxal (77.47 gm, 0.5339 mol) was added and further stirred at 20°C to 35°C for 3-4 hrs. To this reaction mixture, methanol (100 mL) was added and cooled to 0°C to 5°C for 3-4 hrs. The obtained solid was filtered and washed with methanol and dried the compound to obtain pure sodium salt of pyrazine compound of formula (III, 51.8 gm, 69 %, 99.78 % HPLC purity).
Step-2: Preparation of Favipiravir formula (I)
In a Round bottom flask (RBF) sodium salt of pyrazines (III, 0.2 g, 1.2 mmol), selectfluor (1.3 lg, 3.7 mmol), and 18 crown ether (cat.) mmol) and MeCN (8ml) were added and reaction mixture was heated at 85 °C for 12 h. The reaction completion was ensured by TLC. After completion, solvent was removed under vacuum and reaction mixture was stirred into a mixture of EtOAc: H20 (10 ml, 1:1) for 10-15 min. The organic layer was separated, and aq. layer extracted with EtOAc. The combined organic layer was dried over sodium sulfate, filtered, and concentrated to obtain Favipiravir. Example 2: Preparation of 2-aminomalonamide formula (II)
Step-1: Preparation of compound formula (2)
In Round bottom flask (RBF), dialkyl malonate (1, 1.0 kg) was charged and cooled at 0°C to 5°C. To this, acetic acid solution (1197 g acetic acid in 1620 ml water) was slowly added maintaining the temperature below 10°C and further cooled to 0°C to 5°C. To the reaction mixture, sodium nitrite (1300g) was charged portion wise under stirring at same temperature. The reaction mixture was allowed to room temperature (RT) and stirred for 15 to 40 min. Further, the temperature was raised to 40°C to 50°C and stirred for 2 to 3 hours. The reaction completion was ensured by GC and cooled to 25°C to 30°C. To the reaction mixture, 2000 ml methyl tert-butylether (MTBE) was charged and stirred for 30 to 40 min. The aqueous and organic layers were separated. To the aqueous layer, 2000 ml MTBE was charged and stirred for 30 to 40 min. The aqueous and organic layers were separated. To the combined organic layers, 2000 ml water were charged and stirred for 30 to 40 min. The aqueous and organic layers were separated. The pH of organic layer was adjusted between pH 7 to 8 by adding sodium bicarbonate solution. The aqueous and organic layers were separated. The organic layer was washed with saturated brine solution. The organic layer was concentrated to obtain oily mass of compound formula [(2) (1.1 Kg, % yield: 93%)].
Step-2: Preparation of 2-aminopropanediamide (II)
In an autoclave, compound formula (2, 1000 g), methanol (3000 ml) were charged. To this, 5% Pd/C (50% wet) (7.5 g in 3.75 ml water and 7.5 ml methanol) was charged. Autoclave was flushed with Nitrogen (minimum 2 Kg/cm2) followed by hydrogen (pressure minimum 2 Kg/cm2). Hydrogen pressure (10-12 Kg/cm2) was applied and maintained for 30 to 40 min. Raised the temperature to 40°C to 45 °C and stirred for 3 to 5 hours or till hydrogen consumption stopped. Ensured the reaction completion by GC, released hydrogen pressure, and flushed with Nitrogen (minimum 2 Kg/cm2). The reaction mixture was cooled to 25°C to 30°C and filtered through hyflo bed. An autoclave was flushed with methanol (100 mL) and the flushing was used for washing the hyflo bed. The filtrate and washings were combined, and it was transferred into the cleaned autoclave (10 L). The autoclave was flushed with Nitrogen (minimum 2 Kg/cm2). The reaction mixture was cooled at -10°C to 10°C. The ammonia gas pressure (2 to 3 Kg/cm2) was applied at temperature below 10°C. The reaction mixture was allowed to 15°C to 20°C and stirred for 4 to 12 hours maintaining the pressure at 2 to 3 Kg/cm2. Ensured the completion of reaction by HPLC. The reaction mixture was filtered, washed with methanol (1.0L, 1.0V) and the solid was dried under vacuum for 6 to 8 hours to obtain compound formula (II) [472.2g, % yield - 95%, dimer impurity : less than 5.0%, cyclic amide impurity : less than 0.5%, HPLC purity: >96%].

Claims

CLAIM:
1. A process for the preparation of Favipiravir of formula (I) which comprises steps of: (a) reacting a 2-aminomalonamide of formula (II) with glyoxal in presence of reagent to afford pyrazine-amide of formula (III) where R is hydrogen, metal ion;
Figure imgf000012_0001
(b) fluorinating the pyrazine-amide of formula (III) using a fluorinating agent to obtain Favipiravir of formula (I).
Figure imgf000012_0002
2. The process as claimed in claim 1, wherein the 2-aminomalonamide (II) is prepared by a process comprising steps of:
(a) reacting a dialkyl malonate (1) wherein Ri is C1-C4 alkyl, with sodium or potassium nitrite in water in presence of acid to obtain dialkylhydroxyiminomalonate (2);
Figure imgf000012_0003
(b) reducing dialkyl hydroxyiminomalonate (2) using hydrogenating agent in a solvent to obtain dialkyl aminomalonate (3), which is further treated with ammonia in solvent to obtain 2-aminomalonamide of formula (II).
Figure imgf000012_0004
3. The process as claimed in claim 2, wherein the 2-aminomalonamide (II) is substantially pure having purity greater than 95%, where dimer impurity is less than 5%, and a cyclic amide impurity is less than 0.5%.
Figure imgf000013_0001
(dimer impurity) (cyclic amide impurity)
4. A process for the preparation of Favipiravir of formula (I) by reacting pyrazine-amide of formula (III) with a fluorinating reagent, where the pyrazine-amide of formula (III) is prepared by a process claimed in claim 1 (a).
5. The process as claimed in claim 1, wherein said reagent in claim 1 (a) is inorganic base or organic base.
6. The process as claimed in claim 1, wherein pyrazine-amide of formula (III) is isolated as a free acid or metal ion salt where the metal is sodium or potassium.
7. The process as claimed in claim 1 and 4, wherein said fluorinating regent is selected from selectfluor (l-Chloromethyl-4-fluoro-l,4-diazoniabicyclo [2.2.2] octane bis (tetrafluoroborate)), 1 -Fluoropyridinium tetrafluoroborate, 1 -chloromethyl-4-fluoro- l,4-diazoniabicyclo[2.2.2]octane bis(hexafluorophosphate) (FTEDA-PF6), 1-methyl- 4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoro borate) (Selectfluor II), 1- methyl-4-fluoro-l,4-diazoniabicyclo[2.2.2]octanebis(hexafluorophosphate) (Selectfluor II-PF6), N-fluorobenzenesulfonimide (NFSI) and Me-NFSI, l-fluoro-4- hydroxy-l,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) (NFTh) and (1-fluoro- 1 ,3-dihydro-3 ,3-dimethyl- 1 ,2-benziodoxle) fluorobenziodoxole.
8. The process as claimed in claim 1 and 4, wherein fluorinating reaction is carried out in presence or absence of phase transfer catalyst which is selected from 18 crown ether, tetrabutylphosphonium bromide, tetrabutyl ammonium bromide (TBAB), tetrabutyl ammonium fluoride(TBAF), tetrabutyl ammonium chloride, and tetrabutyl ammonium iodide.
9. The process as claimed in claim 1 and 4, wherein the fluorinating reaction is carried out in presence of solvent, which is selected from acetone, methyl isobutyl ketone, acetonitrile, methyl tert -butyl ether, diisopropyl ether, cyclohexane, heptane, toluene, tetrahydrofuran, 2-methyl tetrahydrofuran, 1,4-dioxane, dimethyl sulfoxide.
10. The process as claimed in claim 2, wherein the acid used for preparation of compound (2) is selected from hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, and methanesulfonic acid.
11. The process as claimed in claim 2, wherein the catalyst used in preparation compound formula (II) is selected from platinum oxide, sodium borohydride, Lithium aluminium hydride, palladium on carbon, platinum on carbon and Raney nickel.
12. The process as claimed in claim 2, wherein the solvent used for the preparation of compound (II) is selected from methanol, ethanol, and isopropanol.
PCT/IB2021/055354 2020-06-17 2021-06-17 A simple process for the preparation of favipiravir and its intermediates thereof WO2021255681A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202021025469 2020-06-17
IN202021025469 2020-06-17
IN202021030969 2020-07-20
IN202021030969 2020-07-20

Publications (1)

Publication Number Publication Date
WO2021255681A1 true WO2021255681A1 (en) 2021-12-23

Family

ID=79268553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/055354 WO2021255681A1 (en) 2020-06-17 2021-06-17 A simple process for the preparation of favipiravir and its intermediates thereof

Country Status (1)

Country Link
WO (1) WO2021255681A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418220A (en) * 2000-02-16 2003-05-14 富山化学工业株式会社 Novel pyrazine derivatives or salts thereof, containing the derives or the salts and intermediates for the preparation of both
CN1781911A (en) * 2000-02-16 2006-06-07 富山化学工业株式会社 Intermediate for producing novel pyrazine derivatives
CN102603657A (en) * 2011-10-18 2012-07-25 山东齐都药业有限公司 Preparation method of 6-bromine-3-hydroxyl-2-pyrazinamide
CN104496917A (en) * 2014-12-15 2015-04-08 南京华威医药科技开发有限公司 Synthesis method of Favipiravir

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418220A (en) * 2000-02-16 2003-05-14 富山化学工业株式会社 Novel pyrazine derivatives or salts thereof, containing the derives or the salts and intermediates for the preparation of both
CN1781911A (en) * 2000-02-16 2006-06-07 富山化学工业株式会社 Intermediate for producing novel pyrazine derivatives
CN102603657A (en) * 2011-10-18 2012-07-25 山东齐都药业有限公司 Preparation method of 6-bromine-3-hydroxyl-2-pyrazinamide
CN104496917A (en) * 2014-12-15 2015-04-08 南京华威医药科技开发有限公司 Synthesis method of Favipiravir

Similar Documents

Publication Publication Date Title
US20020013500A1 (en) Process for producing trifluoromethylbenzylamines
WO2021255681A1 (en) A simple process for the preparation of favipiravir and its intermediates thereof
US20090012328A1 (en) Process for preparing bupropion hydrochloride
US20050033088A1 (en) Process for the preparation of phenethylamine derivative, an intermediate of Venlafaxine hydrochloride
EP2999693B1 (en) A process for preparing ivabradine
JP3831954B2 (en) Process for producing 4-hydroxy-2-pyrrolidone
US6689913B2 (en) Process for preparing terbinafine and HCI salt thereof
WO2006067808A1 (en) An improved process for production of intermediate of antidepressant agent
KR20030029816A (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
JP2003261535A (en) Method for producing 2-hydroxy-5-methylpyridine
US6340773B1 (en) Preparation of halogenated primary amines
JP4330270B2 (en) New manufacturing method
JP5396841B2 (en) Process for producing α-trifluoromethyl-β-substituted-β-amino acids
WO2006035457A1 (en) A process for the manufacture of venlafaxine and intermediates thereof
CN113493388B (en) Synthesis method of butenafine hydrochloride
US20060004230A1 (en) Process for the preparation of terbinafine and salts thereof
CN113412255B (en) Process for preparing 4-amino-5-methylpyridinone
CN111018734B (en) Synthesis method of cinacalcet hydrochloride intermediate
TWI385157B (en) A novel intermediate for the preparation of paliperidone
US6930205B2 (en) Process for preparing aminostilbene derivatives
US6331649B1 (en) Process for producing trifluoromethylbenzylamines
JP4441260B2 (en) Process for producing 4-amino-4-phenylpiperidines
WO2010100520A1 (en) A process for preparation of phenethylamine derivative
JPH0586000A (en) Production of 2-amino-4-fluorobenzoic acid
JP4896476B2 (en) Methyloxymethylaminopyridine derivative and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21825738

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21825738

Country of ref document: EP

Kind code of ref document: A1